Program

Program

Our Development Program

GABA_A receptors are involved in the regulation of cognition, memory and learning, motor function, circadian rhythms, neural development, and adult neurogenesis. It is a novel target for the development of therapeutics for several psychiatric disorders. The table below summarizes some psychiatric disorders where cognitive impairment plays a significant role in the disease process.

Cognitive impairment is common in many psychiatric disorders and is a debilitating condition that has a huge impact on patients and their families. Memory consolidation during sleep is often disturbed in these conditions. PTSD (Posttraumatic Stress Syndrome); BPD (Bipolar Disease); OCD (Obsessive Compulsive Disorder).

Gabather has a strong focus on developing novel pro-cognitive drugs that could be used in different psychiatric disorders to restore cognitive function.

GT-002, our most advanced drug candidate, currently in clinical development, is a pro-cognitive small molecule selective GABA_A positive allosteric modulator (PAM), producing both phasic GABA_A-mediated inhibitory potentials and tonic (sustained) inhibition in the brain. 

The functional role of phasic inhibition is to prevent overexcitation of neurons and thereby inhibiting the development of pathological states of network activity leading to excitotoxicity and neuronal death, which is an essential physiological role of GABA-releasing interneurons and GABA_A receptors in the adult CNS.

The GABA_A receptor system is a promising target for the development of novel treatment strategies for mild cognitive impairment (prodromal Alzheimer’s disease), major depressive disorder, anxiety, autism, schizophrenia, and bipolar disorder, where associated cognitive dysfunction is a pronounced symptom associated with the disease.